Treatment With Interferon beta-1b Delays Conversion to Clinically Definite and McDonald MS in Patients With Clinically Isolated Syndromes
Neurol 67:1242-1249, Kappos,L.,et al, 2006
Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006
Tetanus Vaccination and Risk of Multiple Sclerosis: A Systematic Review
Neurol 67:212-215, Hernn,M.A.,et al, 2006
The Clinical Features, MRI Findings, and Outcome of Optic Neuritis in Children
Neurol 67:258-262, Wilejto,M.,et al, 2006
Emerging Monoclonal Antibody Therapies for Multiple Sclerosis
Neurologist 12:171-178, Cree,B., 2006
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Premenstrual Multiple Sclerosis Pseudoexacerbations: Role of Body Temperature and Prevention With Aspirin
Arch Neurol 63:1005-1008, Wingerchuk,D.M. &Rodriguez,M., 2006
Significance of T2 Lesions in Multiple Sclerosis: A 13-Year Longitudinal Study
Ann Neurol 60:236-242, Rudick,R.A.,et al, 2006
Interferon beta-1a Treatment in Childhood and Juvenile-Onset Multiple Sclerosis
Neurol 67:511-513, Tenembaum,S.N. &Segura,M.J., 2006
Obsessive-Compulsive Disorder
BMJ 333:424-429, Heyman,I.,et al, 2006
Does High-Field MR Imaging Have an Influence on the Classification of Patients with Clinically Isolated Syndromes According to Current Diagnostic MR Imaging Criteria for Multiple Sclerosis
AJNR 27:1794-1798, Wattjes,M.P.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Baseline MRI Predicts Future Attacks and Disability in Clinically Isolated Syndromes
Neurol 67:968-972, Tintore,M.,et al, 2006
Community-Acquired Bacterial Meningitis in Adults
NEJM 354:44-53, van de Beek,D.,et al, 2006
Multiple Sclerosis in Twins From Continental Italy and Sardinia: A Nationwide Study
Ann Neurol 59:27-34, Ristori,G.,et al, 2006
Standardized MR Imaging Protocol for Multiple Sclerosis:Consortium of MS Centers Consensus Guidelines
AJNR 27:455-461, Simon,J.H.,et al, 2006
Safety and Tolerability of Interferon Beta-1b in Pediatric Multiple Sclerosis
Neurol 66:472-476, Banwell,B.,et al, 2006
Clinically Isolated Syndromes, A New Oligoclonal Band Test Accurately Predicts Conversion to MS
Neurol 66:576-578, Masjuan,J.,et al, 2006
Metabolic Disease and Stroke: MELAS
emedicine.com, Mandava,P.,et al, 2006
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Multiple Sclerosis - The Plaque and Its Pathogenesis
NEJM 354:942-955, Frohman,E.M.,et al, 2006
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
IM Interferon B-1a Delays Definite Multiple Sclerosis 5 Years After a First Demyelinating Event
Neurol 66:678-684, CHAMPIONS Study Group, 2006
Gray and White Matter Brain Atrophy and Neuropsychological Impairment in Multiple Sclerosis
Neurol 66:685-692, Sanfilipo,M.P.,et al, 2006
Cerebral Sinovenous Thrombosis in the Neonate
Arch Neurol 63:405-409, Fitzgerald,K.C.,et al, 2006
Brain Abnormalities in Neuromyelitis Optica
Arch Neurol 63:390-396, Pittock,S.J.,et al, 2006
Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006
Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should be Treated at the Time of Diagnosis
Arch Neurol 63:614-619, Frohman,E.M.,et al, 2006
Not Every Patient With Multiple Sclerosis Should Be Treated at Time of Diagnosis
Arch Neurol 63:611-619, Pittock,S.J.,et al, 2006
Increase in Multiple Sclerosis Relapse Rate Following in vitro Fertilization
Neurol 66:1280-1281, Laplaud,D.-A.,et al, 2006
Not All Patients With Atrial Fibrillation-Associated Ischemic Stroke Can Be Started on Anticoagulant Therapy
Stroke 37:1217-1220, Somerfield,J.,et al, 2006
Natalizumab: Immune Effects and Implications for Therapy
Ann Neurol 59:731-732, Hauser,S.L. &Weiner, H.L., 2006
MRI T2 Lesion Burden in Multiple Sclerosis. A Plateauing Relationship with Clinical Disability.
Neurol 66:1384-1389, Li,D.K.B.,et al, 2006
Multiple Sclerosis: New Insights and Trends
AJNR 27:954-957, Inglese,M., 2006
Past Adult Lead Exposure is Linked to Neurodegeneration Measured by Brain MRI
Neurol 66:1476-1484,1464, Stewart,W.F.,et al, 2006
Revised Diagnostic Criteria for Neuromyelitis Optica
Neurol 66:1485-1489, Wingerchuk,D.M.,et al, 2006
Treatment of Low Back Pain by Acupressure and Physical Therapy: Randomised Controlled Trial
BMJ 332:696-698,680, Hsieh,L.L.-C.,et al, 2006
Magnetic Resonance Imaging as a Surrogate Outcome Measure of Disability in Multiple Sclerosis: Have We Been Overly Harsh in Our Assessment?
Ann Neurol 59:597-605, Goodin,D.S., 2006
Accuracy of Magnetic Resonance Imaging for the Diagnosis of Multiple Sclerosis: Systematic Review
BMJ 332:875-878, Whiting P.,et al, 2006
Diffusion-Weighted MR Imaging Characteristics of an Acute Strokelike Form of Multiple Sclerosis
AJNR 27:1006-1008, Rosso,C.,et al, 2006
Spinal dural arteriovenous fistulas: a congestive myelopathy that initially mimics a peripheral nerve disorder
Brain 129:3150-3164, Jellema, K., et al, 2006
Chasing "Chasing the Dragon" with MRI: Leukoencephalopathy in Drug Abuse
Br J Radiol 78:997-1004, Bartlett,E. &Mikulis,D.J., 2005
Unusual Presentation of Central Nervous System Cryptococcal Infection in an Immunocompetent Patient
AJNR 26:2522-2526, Saigal,G.,et al, 2005
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
The Ependymal "Dot-Dash" Sign: An MR Imaging Finding of Early Multiple Sclerosis
AJNR 26:2033-2036, Lisanti, C.J.,et al, 2005
Adrenoleukodystrophy
JAMA 294:3131-3134, Moser,H.W.,et al, 2005
MRI T2 Hypointensity of the Dentate Nucleus is Related to Ambulatory Impairment in Multiple Sclerosis
J Neurol Sci 234:17-24, Tjoa,C.W.,et al, 2005
Recommended Standard of Cerebrospial Fluid Analysis in the Diagnosis of Multiple Sclerosis, A Consensus Statement
Arch Neurol 62:865-870, Freedman,M.S.,et al, 2005
Life-Threatening Acute Pancreatitis Associated with Interferon Beta-1a Treatment in Multiple Sclerosis
Neurol 65:170-171, Midgard,R.,et al, 2005